Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Argentina Lithium Exercises Property Options at Rincon West and Antofalla North (click to learn more) Heritage Mining - Drill Program Update and Planned Alcona Phase II Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera. The Company has received approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection), and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.


NDAQ:SCYX - Post by User

SCYNEXIS Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(119)
•••
  • JonathanJSmithX
Comment by JonathanJSmithon Mar 31, 2022 12:33pm
78 Views
Post# 34563469

RE:RE:BREXAFEMME - published User side effects

RE:RE:BREXAFEMME - published User side effects Yeah, I agree - worse sales than I had expected.

They should get a pop however when they submit their supplemental NDA vis-a-vis rVVC in Q2.

I'm still holding as their MC is hovering around cash on hand. BTW, Burry sold his position a while ago.

Cheers and good luck,

JJ
<< Previous
 Bullboard Posts
Next >>